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Abstract  
The microenvironment is an essential component of tumors and plays a 
role in malignant transformation and progression. At this moment the 
composition of the B cell lymphoma microenvironment is largely 
unknown. 
We analyzed the cellular composition of follicular lymphoma (FL), and 
diffuse large B cell lymphoma (DLBCL) to reactive lymph nodes (RLN) 
for 44 subpopulations by flow cytometry. In addition, we performed 
gene expression profiling of purified CD4+ and CD8+ T cells.  
We observed, less NK cells, macrophages and terminally differentiated 
CD4+ T cells and more TIA+CD8+ cells in lymphoma compared to RLN. 
The percentages of CD69+CD3+ T cells, CD69+CD8+ cells and T 
follicular helper (CXCR5+ICOS+) cells were higher and of CD8+ cells 
were lower in FL than in RLN. In DLBCL, higher proportions of 
CD69+CD8+, Granzyme B+CD8+ and less CD127low regulatory T cells 
(Tregs) were found compared to RLN. Comparison of activated B cell 
type (ABC-) to germinal center B cell type (GCB-) DLBCL revealed more 
CD57+CD4+, TIA-1+CD4+ and CXCR4+CD8+ cells in ABC-DLBCL and 
more CD127low Tregs in GCB-DLBCL. Gene expression profiling 
revealed low numbers of differential expressed genes. Higher expression 
of TIGIT, a marker of exhaustion, in activated CD8+ T cells was observed 
in all NHL.  
In conclusion, the microenvironment of B cell lymphomas is composed of 
a distinct set of cells that are potentially able to respond to the malignant 
cells. Some evidence of exhaustion of the CD8+ T cells is found and is 
interesting for therapeutic interventions such as with PD-1 inhibition. 
 
Keywords: microenvironment, non-Hodgkin lymphoma, T cells 
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Introduction 
Diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL) 
are two main non-Hodgkin lymphoma (NHL) subtypes that originate 
from germinal center B cells. Together they compose 60% of all 
lymphomas1. 25-30% of the FL patients transform towards a more 
aggressive lymphoma subtype with transformation to DLBCL being 
most common2. FL has been considered as an indolent lymphoma, while 
DLBCL is an aggressive lymphoma3. DLBCL can be further divided into 
two subgroups based on their gene expression profile. These two 
subgroups are referred to as germinal center B cell like (GCB-)DLBCL 
and non-germinal center or activated B cell like DLBCL (ABC-DLBCL)4.  
Recent studies demonstrated a prominent role for the microenvironment 
in malignant formation and progression of NHLs5. Changes in the 
percentages of regulatory T cells (Treg)6 and follicular dendritic cells7, 
can result in immune tolerance or even provide survival signals to the 
lymphoma cells. Previous studies showed differences in percentages of T 
follicular helper cells (Tfh), Treg and cytotoxic T cells (CTL) in FL 
compared with reactive lymph nodes (RLN). Moreover, the percentages 
of specific T cell subsets are prognostic factors in FL8,9. However, the 
cellular composition of the microenvironment of NHL is not completely 
clear yet.  
In this study, we investigated differences in the cellular composition of 
the microenvironment of NHL with a specific focus on T cell subsets. We 
determined whether there were differences in the cellular composition 
between the NHL subtypes and in comparison to RLN. In addition, we 
studied whether there were significant differences between the gene 
expression profiles of CD4+ and CD8+ T cell subsets isolated from the 
NHL and RLN. 
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Study cohort 
Single cell suspensions of biopsies from NHL patients were collected and 
stored at -196°C from 1999 till 2012. The samples were classified 
according to the 2008 World Health Organization (WHO) criteria and the 
Hans algorithm10 was used for classification of DLBCL cases into GCB 
and ABC subtypes. We included seven patients with FL (five grade I and 
two grade I and II), six patients with transformed FL (TFL), six patients 
with GCB-DLBCL and seven patients with ABC-DLBCL. FL and DLBCL 
cases were all derived from primary tumor samples. One TFL and one 
ABC case were of splenic origin, all other tissues were from lymph 
nodes. The TFL cases were cases containing both FL and DLBCL in the 
primary case, or were DLBCL cases of patients that had FL in the past. 
We also included, as a control, seven reactive lymph nodes with 
lymphoid hyperplasia (RLN). The study protocol was consistent with 
international ethical and professional guidelines (the Declaration of 
Helsinki and the International Conference on Harmonization Guidelines 
for Good Clinical Practice). 
 
Flow cytometry 
Optimized concentrations of fluorochrome-antibody conjugates were 
applied on all samples for 44 different subpopulations of cells 
(supplementary Table 1). Intracellular stainings were performed using 
the fixation and permeabilization kit (Ebioscience) after staining for cell 
surface markers. Flow cytometry analysis was performed using BD FACS 
Calibur flow cytometer and Calibur software (BD Biosciences, San Jose, 
CA). Single stains were performed to optimize the compensation for the 
fluorochromes. Raw flow cytometry results were analyzing by WinList 
software. Statistical analysis was performed with IBM SPSS Statistics 22. 
The Kruskal-Wallis test (p<0.0125 was considered as significant, to 
correct for multiple testing) and the Mann-Whitney post-hoc test (p<0.05 
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was considered as significant) was used to compare percentages in 
unpaired samples. All analyses were two-tailed. 
 
Cell purification and activation 
CD4+ and CD8+ cells were isolated from single cell suspensions using 
positive selection with the Dynabeads CD4+ and CD8+ Isolation Kit 
(Invitrogen, Carlsbad, USA) according to the manufacturer’s instructions. 
The purities of the subsets of cells after isolation were determined by 
flow cytometry. Half of the purified CD4+ and CD8+ cells were activated 
by incubation of soluble CD3 (1ng/ml) and CD28 (100ng/ml) antibodies 
for six hours. 
 
RNA extraction 
Total RNA was isolated with the RNeasy Mini Kit or RNeasy Micro Kit 
(Qiagen, Carlsbad, CA USA) according to the manufacturer’s protocol. 
The RNA yield was measured on a NanoDrop ND-1000 
Spectrophotometer (NanoDrop Technologies, Wilmington, DE USA). 1% 
agarose gels were used to check the integrity of the RNA by inspection of 
the ribosomal bands. Only good quality RNA samples were used for 
further experiments. 
 
Gene expression profiling 
Samples were hybridized on a custom designed array that contained all 
protein-coding gene probes derived from AMADID #028004 (Agilent 
Technologies, Santa Clara, CA, USA). Sample labeling was performed 
according to the manufacturer’s instructions using 25-40ng total RNA 
and the dual-color Low Input Quick Amp Labeling Kit in combination 
with Cyanine 3 and 5 CTP Dye Packs (Agilent Technologies). RNA from 
CD4+ and CD8+ cells was labeled with Cyanine 5 and Cyanine 3, 
5 
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respectively. Labeled cRNA was purified with the RNeasy Mini Kit 
(Qiagen) and quantified with a Nanodrop ND-1000. Scanning and 
analysis of the array was performed with the Agilent DNA Microarray 
Scanner and Agilent Feature Extraction software version 10.7.3.1. Raw 
data were loaded into GeneSpring GX 12.5 software (Agilent 
Technologies), log2 transformed and quantile normalized without 
baseline transformation. For data analysis, samples were divided into 4 
groups (CD4+ and CD8+ resting and CD4+ and CD8+ activated) that 
were analyzed separately. Per group probes were included if detected 
above the background in at least 50% of the samples in one out of four 
conditions (conditions: DLBCL, FL, TFL and RLN). Using these criteria, 
22,086 and 22,931 probes were included in CD4+ resting and activated 
cells respectively. For CD8+ resting and activated cells, 17,862 and 17,409 
probes were included. Statistical differences per group were identified by 
Welch ANOVA test using Benjamin Hochberg multiple testing correction 
and Tukey’s HSD post-hoc test. For the final selection of probes an 
additional ≥2-fold change in expression criterion was applied. Genesis 
software v1.7.6 (22) (Institute for Genomics and Bioinformatics Graz, 
Graz, Austria) was used to generate the heatmaps with Euclidean 
distance. 
 
Validation by qPCR 
60ng RNA was used as input for the cDNA synthesis using Superscript II 
and random primers according to the manufacturer’s protocol 
(Invitrogen, Bleiswijk, Netherlands). Primers used were for  
GPR133 forward 5’-GACCCCCTGCCAAGTGATG-3’ and reverse 5’-
TCCATGCGAAGGCACTCA-3’, for CASR forward 5’- 
CAGATGCCAGTGCCTGTAACA-3’ and reverse 5’-
GGAGGTGTGGTTCTCATTGGA-3’, for ADAM19 forward 5’-
TGAATGTGGCAGGAGACACC-3’ and reverse 5’-
GGATCTTCCCACACTTCGCA-3’, for FAM78B forward 5’-
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CGTGCAATCAGATGGAGTTCTTC-3’ and reverse 5’-
GGCAGTTCCCAGCTTGACAT-3’, for PRICKLE1 forward 5’-
GCATCGGATTAAACAGCTTTTGT-3’ and reverse 5’-
GACTGGCAATACCGTACCTCATT-3’, CD82 for forward 5’-
GTGGATCCTGGCCGACAA-3’ and reverse 5’-
CGAGCTGGAGGAGGTTTGC-3’, for TIGIT forward 5’-
TCCCCTCGCCTCAGGAAT-3’ and reverse 5’-
GCAGAAATGTTCCCCGTTGT-3’, for BTN3A2 forward 5’- 
TCTTCGTCCGATACCAATAAGTCA-3’ and reverse 5’-
AGGCTTGAAGAGGGCCATTT-3’, for VCAM1 forward 5’- 
AAGGCAGAGTACGCAAACACTTT-3’ and reverse 5’-
GCTGACCAAGACGGTTGTATCTC-3’ and for C5orf39 forward 5’-
CTCTCCATCCCTGGGACAGA-3’ and reverse 5’-
AAAAGGCACCCGCTGTCA-3’.  
The qPCR reaction was performed in triplicate in a final volume of 10µl 
consisting of 5µl 2x SYBR Green master mix (Applied Biosystems, Foster 
City, CA USA), 1µl of forward and 1µl of reverse primer (300mM) and 
2.5µl of cDNA (1ng). Amplification was performed on a Roche 
LightCycler® 480 Instrument (Roche, Almere, Netherlands). For 
determining relative expression levels, HPRT was used as a 
housekeeping gene and 2-ΔCp values were calculated. 
 
Results 
The main immune cell populations  
Characteristic of the study cohort were summarized in Table 1. The 
median percentages of B cells (CD20+) and T cells (CD3+) in TFL and 
DLBCL were similar to RLN. In FL, the median percentage of B cells was 
higher and the median percentage of T cells lower, but the difference 
were not significant. This is probably a reflection of the higher 
percentage of tumor cells in the cell suspensions of FL (Fig. 1A, B). 
5 
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Analysis of the main T cell populations revealed similar percentages of 
Th cells (CD4+) in RLN and the three NHL groups (Fig. 1C). In FL the 
median percentage of CTL cells (CD8+) was significantly lower (median 
6%) as compared to RLN (median 13%) (Fig. 1D). The only difference 
observed between the three lymphoma groups was a significantly higher 
percentage of CD8+ in TFL and DLBCL compared to FL. The percentages 
of NK cells (CD56+) were significantly decreased in all three NHL 
subtypes in comparison to RLN, i.e. a median of 14% in RLN and 
medians of 4%, 7% and 6% for FL, TFL and DLBCL, respectively. (Fig. 
1E). A similar pattern was observed for the number of macrophages 
(CD68+), which comprised 8% of the cells in RLN, 1% in FL, 4% in TFL 
and 3% in DLBCL (Fig. 1F).  
 
Table 1. The characteristics of the study cohort 
Clinical 
characteristic RLN FL TFL DLBCL GCB ABC 
Gender 
Male (%) 4 (57) 5 (71) 2 (33) 9 (69) 3 (50) 6 (86) 
Female 
(%) 3 (43) 2 (29) 5 (67) 4 (31) 3 (50) 1 (14) 

















RLN: reactive lymph node 
FL: follicular lymphoma 
DLBCL: diffuse large B cell lymphoma 
GCB: germinal center B cell like diffuse large B cell lymphoma 
ABC: activated B cell like diffuse large B cell lymphoma 
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Figure 1. Proportion of main populations in reactive lymph node (RLN) and 
non-Hodgkin lymphomas (follicular lymphoma, FL; transformed follicular 
lymphoma, TFL; diffuse large B cell lymphoma, DLBCL). Percentages of 
CD20+ cells (A), CD3+ cells (B), CD4+ cells (C), CD8+ cells (D), CD56+ cells (E), 
CD68+ cells (F) in total cells. Within the DLBCL group, open triangles represent 
GCB-DLBCL cases and closed triangles indicate ABC-DLBCL. Lines indicate the 
median percentage per group. Kruskal-Wallis test was used to compare all four 
groups and Mann-Whitney U test was used to compare the difference between 





Differences within specific T cell, NK cell and macrophage subsets 
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The percentage of early activated (CD69+) cells in the CD3+ T cells was 
higher in FL (median 57%) than in RLN (median 38%), while the 
percentage was not significantly different between RLN and either TFL 
or DLBCL (Fig. 2A). Significant differences were also observed between 
FL and TFL (median 24%) and between TFL and DLBCL (median 48%). 
The percentage of CD69+ cells also showed significant differences in 
CD8+ T cells, but not within the CD4+ T cells, indicating that the 
differences observed in the CD3+ population are caused by differences 
within CD8+ CTLs. The percentage of CD69+ cells in CD8+ T cells was 
higher in FL (median 63%) and DLBCL (median 51%) as compared to 
RLN (median 38%). Significant differences were also observed between 
FL and TFL (median 31%) and between TFL and DLBCL (Fig. 2B). The 
difference between CD69+CD8+ in CD3+ T cells in DLBCL and RLN 
remained significantly different, as did the differences between FL and 
TFL, and between TFL and DLBCL (Fig. 2C). 
The percentages of Tregs were studied using four different markers 
(FoxP3, GITR, CTLA-4, and CD127low). Only the frequency of the 
CD127low in the CD25+CD4+ (CD127low Tregs) showed a significant 
difference between DLBCL (median 4%) as compared to RLN (median 
10%) and TFL (median 9%) (Fig. 2D). No differences were found in the 
percentages of CD127lowCD25+CD4 in CD3+ T cells between these 
groups (Fig. 2E and Supplementary Table S2.).  
The percentage of TIA-1+ cells in CD8+ T cells was significantly 
increased in all three NHL subgroups as compared to RLN. The median 
percentage of TIA-1+ cells was 37% in RLN, 68% in FL, 76.5% in TFL and 
84% in DLBCL (Fig. 2F). Significant differences remained in TIA-1+CD8+ 
cells in CD3+ T cells for FL and DLBCL, but not for TFL (Fig. 2G).  
Analysis of Tfh cells revealed that the percentage of CXCR5+ICOS+CD4+ 
cells in the CD3+ subpopulation was significantly different between RLN 
(median 11%) and FL (median 21%) and between FL and DLBCL 
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(median 4%). The differences in CXCR5+ICOS+ cells did not reach 
significance in CD4+ T cells (Fig. 2H, I).   
Discrimination of CD4 subsets based on the differentiation markers 
CCR7 and CD45RA indicated  that the percentage of CCR7-
CD45RA+CD4+ cells (TEMRA cells) in CD3+ T cells was significant 
lower in FL (median 16%), TFL (median 5.5%) and DLBCL (median 13%) 
as compared to the median percentage in RLN (median 31%. A similar 
pattern was seen within the CD4+ T cells, but these differences were not 
significant (Fig. 2J, K). 
 
Figure 2. Proportion of subpopulations in normal lymphoid (reactive lymph 
node, RLN) and germinal center derived non-Hodgkin lymphomas (follicular 
lymphoma, FL; transformed follicular lymphoma, TFL; diffuse large B cell 
lymphoma, DLBCL). Percentages of CD69+ cells in CD3+ cells (A), CD69+ cells 
in CD8+cells (B), CD69+CD8+ cells in CD3+ cells (C), CD127low cells in 
CD25+CD4+ cells (D), CD127lowCD25+CD4+ cells in CD3+ cells (E), TIA-1+ 
5 
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cells in CD8+ cells (F), TIA-1+ CD8+ cells in CD3+ cells (G), CXCR5+ICOS+ cells 
in CD4+ cells (Tfh cells) (H), CXCR5+ICOS+CD4+ cells in CD3+ cells (I), CCR7-
CD45RA+ cells in CD4+ cells (TEMRA cells) (J), CCR7-CD45RA+CD4+ cells in 
CD3+ cells (K), Granzyme B+ cells in CD8+ cells (L), Granzyme B+CD8+ cells in 
CD3+ cells (M). Within the DLBCL group, open triangles represent GCB-DLBCL 
cases and closed triangles represent the ABC-DLBCL cases. Lines indicate the 
median percentage per group. Kruskal-Wallis test was used to compare all four 
groups and Mann- Whitney U test was used to compare the difference between 
the groups. (*: p<0.05; **: p<0.01; ***: p<0.001) 
 
Significantly higher percentages of Granzyme B+ CD8+ cells CTLs were 
found in CD3+ T cells in DLBCL (median 12%) compared to RLN 
(median 3%), FL (median 5%), and TFL (median 7%). The median 
percentage of Granzyme B+ cells in CD8+ cells showed the highest 
frequency in DLBCL, but these differences were not significant (Fig. 2L, 
M). 
No differences were observed in the other populations studied 
(Supplementary Table S2).  
 
Differences between GCB-DLBCL and ABC-DLBCL 
To compare the percentages of the different subpopulations between 
GCB and ABC-DLBCL, we divided the TFL and DLBCL cases into GCB 
or ABC-DLBCL according to the Hans algorithm. The median percentage 
of CD57+ cells in CD4+ cells was significantly lower in GCB-DLBCL 
(median 20%) as compared with ABC-DLBCL (median 36%) (Fig. 3A). 
The percentage of CD57+CD4+ cells was not significantly different in the 
CD3+ T cells (Fig. 3B). The percentage of CD127low cells in CD25+CD4+ 
cells was significantly higher in GCB-DLBCL (median 8%) compared to 
ABC-DLBCL (median 1%)(Fig. 3C), but CD127lowCD25+CD4+ cells 
were not different in CD3+ T cells (Fig. 3D) . The percentage of TIA-1+ 
cells was significantly lower in CD4+ cells in GCB-DLBCL (median 14%) 
than in ABC-DLBCL (median 29%)(Fig. 3E). There was a similar trend of 
TIA-1+CD4+ cells in CD3+ T cells but this did not reach significance (Fig. 
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3F). The percentage of CXCR4+ cells in CD8+ cells was significantly 
higher in ABC-DLBCL (median 25%) as compared to the GCB-DLBCL 
group (median 10.5%)(Fig. 3G). This difference was also significant in 
CXCR4+CD8+ cells in CD3+ T cells with a median of 10% in ABC-
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Figure 3. Proportion of subpopulations in germinal center B cell like diffuse 
large B cell lymphoma (GCB-DLBCL) and activated B cell like diffuse large B 
cell lymphoma (ABC-DLBCL). Percentages of CD57+ cells in CD4+ cells (A), 
CD57+CD4+ cells in CD3+ cells (B), CD127low cells in CD25+CD4+ cells (C), 
CD127lowCD25+CD4+ cells in CD3+ cells (D), TIA-1+ cells in CD4+ cells (E), 
TIA-1+ CD4+ cells in CD3+ cells (F), CXCR4+ cells in CD8+ cells (G), 
CXCR4+CD8+ cells in CD3+ cells (H). Lines indicate the median percentage per 
group. Mann-Whitney U test was used to compare GCB to ABC-DLBCL. (*: 
p<0.05) 
 
Gene expression studies in purified CD4 and CD8 T cell subsets 
We next applied gene expression profiling on CD4+ and CD8+ T cells to 
establish putative differences in comparison to RLN. The median purity 
of CD4+ T cells was 88% (range 86 – 98%) and for the CD8+ T cells the 
median purity was 98% (range 88 – 100%) (Supplementary Fig. S1). We 
first compared the gene expression profile of the resting cells with the 
activated cells. For CD4+ T cells, there were 5,964 probes differentially 
expressed after activation, of those the expression level of 1,753 probes 
changed at least 2-fold. For CD8+ T cells, 7,211 probes were differentially 
expressed after activation, of which 2,512 probes had a difference of at 
least 2-fold. This shows that the CD4+ and CD8+ T cells can be activated 
and are not anergic. We next examined whether there were any changes 
in gene expression levels between the NHL subgroups and RLN. After 
filtering for at least 2 fold differences in comparison to RLN, 17, 13, 2 and 
28 genes were significant in CD4+ resting, CD4+ activated, CD8+ resting 
and CD8+ activated T cells, respectively (Table 2, Fig. 4). The low 
numbers of differentially expressed genes indicates that the expression 
profiles of the lymphoma derived T cells are quite similar to those of the 
RLN derived T cells. Validation of differential expression patterns by 
qRT-PCR was performed for eight differentially expressed genes 
involved in the immune response and cell signaling in CD4+ resting cells 
(GPR133), CD4+ activated cells (ADAM19 and CASR), and CD8+ 
activated cells (CD82, TIGIT, BTN3A2, VCAM1, and ANXA2R) and for 
both genes found differentially expressed in resting CD8+ cells (FAM78B 
 
Composition of microenvironment in B cell lymphoma  
123 | P a g e  
(cell development) and PRICKLE1 (DNA repair)). Sixteen out of twenty-
two comparisons showed the same pattern as the array results (Table 3, 
Supplementary Fig. 2).  
 
 
Figure 4. Heatmaps for genes that are more than two-fold differentially 
expressed in purified CD4+ and CD8+ cells derived from different types of 
NHLs compared with RLN. (A-C) resting CD4+ cells in FL (A), TFL (B) and 
DLBCL (C) compared with RLN. (D-F) Activated CD4+ cells in FL (D), TFL (E) 
and DLBCL (F) compared with RLN. (G-I) resting CD8+ cells in FL (G), TFL (H) 
and DLBCL (I) compared with RLN. (J-L) Activated CD8+ cells in FL (J), TFL 
(K) and DLBCL (L) compared with RLN. Student T test was used to compare 
between RLN and NHL. 
5 
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Table 2. Number of differentially expressed genes in (resting and 
activated) CD4+ and CD8+ cells in NHLs compared with RLN 








WELCH+BH 34 19 3 32 






RLN 12 9 2 22 
TFL vs 
RLN 9 11 2 24 
DLBCL vs 
RLN 3 5 2 23 
BH: Benjamin Hochberg multiple testing correction  
 





The aim of this study was to determine the cellular composition of three 
B-cell derived lymphomas and identify differences with RLN at the 
composition or gene expression level. Most differences in cellular 
composition were observed between one or more of the lymphoma 
 FL TFL  DLBCL  FL  TFL  DLBCL
CD4+ resting GPR133 - - - -
CASR - -
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groups in comparison to RLN and only a few differences were observed 
between lymphoma groups. At the gene expression level, only a limited 
number of differentially expressed genes were identified in the 
comparison between the three lymphoma subtypes and the RLN group. 
 
Comparison of NHL with RLN 
In comparison to RLN, less NK cells, macrophages and TEMRA cells as 
well as more TIA-1+CD8+ cells were observed in NHLs. In the 
comparison within the lymphoma subgroups, DLBCL had the most 
unique cellular composition. The presence of NK cells has been described 
in lymphoma, with median levels of 3% in DLBCL11. Specifically, NKT 
cell percentages were reported to be higher in DLBCL (median 12.2%) as 
compared to other NHLs, such as FL12, however comparisons with RLN 
have not been made so far. In our study, fewer CD56+ NK cells were 
found in NHL compared with RLN and no difference was found in the 
percentages of NKT cells in NHLs compared to RLN or between NHL 
subtypes. NK cells react more profound to discontinuously presented 
activating receptors as compared to continuously presented activating 
receptors13. This might indicate that NK cells are hypo-responsive to 
activating receptors expressed by tumor cells14.  
TEMRA cells are in the last stage of Th cell differentiation, so although 
effector functions are still present, they are not capable of proliferating 
any longer15, and within the TEMRA cells a large population of cells is 
senescent16. The high numbers of TEMRA cells we found in RLN are 
probably reflecting a chronic stimulation of the cells. The lower number 
of TEMRA cells in NHL could indicate that there is no active immune 
response, since the number of TEMRA cells are  increased during an 
active immune response such as for example transplantation rejection17.  
 Ai et al showed increased numbers of FoxP3+CD4+ cells in FL as 
compared to tonsil, more FoxP3+CD25+CD4+ cells in FL compared to 
5 
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DLBCL and tonsil, and more FoxP3+CD25+CD4+ cells in FL than in 
RLN. FL tumor cells can induce conversion of Th cells to Tregs18. 
CD4+CD25+ Tregs can block the function of CD8+ cells by the 
production of TGF-β19. Although we did not find differences in FoxP3+ 
Tregs percentages in our study, we did find reduced numbers of natural 
occurring Tregs (CD127lowCD25+CD4+ cells) in DLBCL compared to 
RLN and TFL. Increase of numbers of natural occurring CD127low Tregs 
has been associated with an environment that supports escape of the 
tumor cells to immune surveillance and malignant transformation20. 
Reduced numbers of CD127low Tregs in DLBCL does not fit with these 
data and the character of DLBCL.  
The percentage of CXCR5+ICOS+ Tfh cells has been reported to be 
increased in FL compared to RLN (median 32% vs 20%)21, while these 
cells are almost non-existent in DLBCL (median 0.2%)22. Our findings on 
Tfh cells, i.e. higher percentages in FL than RLN and lower percentages 
in DLBCL compared to FL, are in line with this. In FL, Tfh have been 
described to assist the survival of malignant cells23. The loss of Tfh cells 
in DLBCL can be the cause or the result of loss of the follicular structure 
in DLBCL. In FL the follicular structure has been retained consistent with 
the higher number of Tfh cells24.  
Previous studies showed that within FL 6% of the cells are CD8+25, we 
observed a similar percentage of CD8+ cells in FL. In TFL and DLBCL the 
percentages were higher, i.e. 9% and 16%, respectively.  We showed 
increased percentages of TIA-1+CD8+ cells in all lymphoma subgroups 
compared to RLN and increased percentages of Granzyme B+ CD8+ cells 
in DLBCL compared with RLN and the other lymphoma subgroups. The 
presence of CD8+ cells would normally indicate an active anti-tumor 
immune response. Despite the higher numbers of TIA-1+ and Granzyme 
B+ CD8+ cells, DLBCL is not characterized by a better prognosis.  
 
Comparison of GCB-DLBCL with ABC-DLBCL 
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Differences between GCB and ABC-DLBCL in the microenvironment 
have not been described so far. ABC-DLBCL had more CD57+CD4+ cells, 
TIA-1+CD4+ cells and CXCR4+CD8+ cells and less CD127low Tregs 
compared with GCB-DLBCL. We previously showed that CD57+CD4+ 
cells also express PD-126, and thus represent Tfh cells. These Tfh cells, are 
probably exhausted T cells as ABC-DLBCL express more PD-1L27. 
Expression of CD57 has been associated with senescence as well as 
exhaustion28, and PD-1 is one of the hallmarks of exhaustion29. The 
increase in TIA-1+ Th cells in ABC and the loss of CD127low Tregs 
compared to GCB as we found in this study, suggests that the immune 
response in ABC-DLBCL remained active, which does not fit with the 
more aggressive behavior of ABC-DLBCL.  
Naoki et al, showed an inverse association between the expression level 
of CXCR4 and perforin in CD8+ cells30. This indicates that the higher 
percentage of CXCR4+CD8+ cells as we observed in ABC-DLBCL 
compared to GCB-DLBCL might indicate presence of less active CD8+ 
cells in ABC-DLBCL. 
 
Gene expression profiling of sorted CD4+ and CD8+ T cells 
All the findings so far indicated that, due to the high frequency of CTLs 
and low frequency of Treg cells the immune response in NHL is 
activated. To further investigate this, we applied gene expression 
profiling on CD4+ and CD8+ T cells. This revealed a limited number of 
differentially expressed genes in resting or activated CD4+ and CD8+ T 
cells of NHLs compared to RLN. This implicates that the overall nature 
of the T cells in the lymphoma samples is not different from those in 
RLN. Activation with αCD3 and αCD28 induced significant differences 
in gene expression patterns, indicating that these T cells can be activated. 
This shows that these cells are not anergic but possibly might be 
exhausted29,31. T cell exhaustion which is induced by consistent antigen 
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due to high expression of inhibitory receptors, and decreased secretion of 
immune regulatory cytokines29. T cell exhaustion can be converted by 
early removal of antigens, blocking  inhibitory receptors (PD-1) or 
blocking of immune suppressive cytokines (IL-10), while anergy is hard 
to convert32,33. For most of the differentially expressed genes the potential 
role in the pathogenesis of NHL is still unknown. TIGIT (T cell 
immunoglobulin and immunoreceptor tyrosine-based inhibitory motif 
domain) was upregulated in activated CD8+ cells in NHL compared to 
RLN. TIGIT is one of the hallmarks of T cell exhaustion32. Furthermore, 
Johnston et al. found that TIGIT is expressed by infiltrating cells in 
several solid tumors and that, in cancer models in mice, treatment with 
anti-TIGIT antibody enhanced the immune response by inducing IFN-γ 
production by CD8+ cells34. Therefore, the elevated expression of TIGIT 
in CD8+ T cells in NHLs can lead to the reduction of the cytotoxicity in 
clearing malignant cells. Anti-TIGIT treatment might be a future strategy 
to rebuild immune reactivity of CD8+ T cells against the B cell lymphoma 
cells.  
In conclusion, the composition of the infiltrating immune cells in NHLs 
are different from those in RLN, with especially in DLBCL all ingredients 
being present for an effective anti-tumor immune response. Since that 
immune response is not functional, we propose that the T cells are 
exhausted. Especially the CD8+ cells in ABC-DLBCL with the expression 
of CXCR4 and enhanced expression levels of TIGIT, combined with the 
increase in CD57+CD4+ cells fits with this concept.  
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Supplementary table S1. Overview of the 44 subsets studied  
 
BD: BD Biosciences; IQ: IQ Products, Groningen, Netherlands; R&D: R&D 
systems, Minneapolis, MN USA; Dako: Dako Products, Glostrup, Denmark; BC: 
Beckman Coulter, Woerden, Netherlands. 
  
Leukocyte subpopulation Immunophenotype Company
B cells CD20+ BD
T cells CD3+ Dako
NK cells CD56+ IQ
Macrophages CD68+ R&D
Th cells CD4+ BD
Cytotoxic T cells CD8+ BD
CD69+ in CD3+ IQ/Dako
CD69+ in CD4+ IQ/BD
CD69+ in CD8+ IQ/BD
CD25+ in CD4+ IQ/IQ
CD25+ in CD8+ IQ/BD
FoxP3+ in CD4+ BD/BD
GITR+ in CD4+ R&D/BD
CD127low in CD4+ BD/BD
CD152+ in CD4+ BD/IQ
CD45RA+ in CD4+ Own lab/BD
CD45RBhighCD45RO- in CD4+ Own lab/Own lab/BD
CD45RBhighCD45RO+ in CD4+ Own lab/Own lab/BD
CXCR3+ in CD4+ R&D/IQ
CD45RBlowCD45RO+ in CD4+ Own lab/Own lab/BD
CXCR4+ in CD4+ R&D/IQ
Truly Naïve Th cells CCR7+CD45RA+ in CD4+
Central memory Th cells CCR7+CD45RA- in CD4+
Effector memory Th cells CCR7-CD45RA- in CD4+
Terminal differentiated effector Th cells CCR7-CD45RA+ in CD4+
FoxP3+CD25+ in CD4+ IQ/BD/BD
GITR+CD25+ in CD4+ IQ/R&D/BD
CD127lowCD25+ in CD4+ IQ/BD/BD
CD152+CD25+ in CD4+ BD/IQ/IQ
Granzyme B+ in CD4+ BD in IQ
TIA-1+ in CD4+ BC in IQ
CXCR5+ICOS+ in CD4+ R&D/BD/BD
CD57+ in CD4+ BD/BD
Tfh regulatory cells CXCR5+ICOS+ in CD4+CD25+ R&D/BD/BD/IQ
Granzyme B+ in CD8+ BD/BD
TIA-1+ in CD8+ BC/BD
CXCR3+ in CD8+ R&D/BD
CXCR4+ in CD8+ R&D/BD
CD16+ in CD56+ R&D/IQ
CD69+ in CD56+ IQ/IQ
CD107a+ in CD56+ BD/IQ
NK T cells CD56+ in CD3+ IQ/BD
CD163+ R&D
CD163+ in CD68+ R&D/R&D
M2 Macrophages
Suppression of Th cells
Activation of T cells
Cytotoxic Th cells
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Supplementary table S2. Statistical analysis of 44 cell 
populations 
 
K-W: Kruskal-Wallis Test; M-W: Mann-Whitney U test. P value with bold 
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Supplementary figure S1. Percentage of purity of CD4+ and CD8+ cells. (A) 
Mean±SD percentage of purity of purified CD4+ cells isolated from RLN, FL, 
TFL and DLBCL cells suspension. (B) Mean±SD percentage of purity of purified 
CD8+ cells isolated from RLN, FL, TFL and DLBCL cells suspension. 
 
 
Supplementary figure S2. Validation by qRT-PCR of differentially expressed 
genes. (A-B) Between resting CD4+ cells isolated from RLN and FL. (A) GRP133 
expression in resting CD4+ cells as detected by microarray. (B) expression level 
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of GPR133 in resting CD4+ cells detected by qRT-PCR. (C-F) Between activated 
CD4+ cells isolated from RLN, FL and TFL. (C) expression level of CASR in 
activated CD4+ cells as detected by microarray.  (D) expression level of CASR in 
activated CD4+ cells detected by qRT-PCR. (E) expression level of ADAM19 in 
activated CD4+ cells detected by microarray. (F) expression level of ADAM19 in 
CD4+ cells detected by qRT-PCR. (G-J) Between resting CD8+ cells isolated from 
RLN and NHL. (G) expression level of FAM78B in resting CD8+ cells detected 
by microarray. (H) expression level of FAM78B in resting CD8+ cells detected by 
qRT-PCR. (I) expression level of PRICKLE1 in resting CD8+ cells detected by 
microarray.(J) expression level of PRICKLE1 in resting CD8+ cells detected by 
qRT-PCR. (K-T) Between activated CD8+ cells isolated from RLN and NHL. (K) 
expression level of CD82 in activated CD8+ cells detected by microarray. (L) 
expression level of CD82 in activated CD8+ cells detected by qRT-PCR. (M) 
expression level of TIGIT in activated CD8+ cells detected by microarray. (N) 
expression level of TIGIT in CD8+ cells detected by qRT-PCR. (O) expression 
level of BTN3A2 in activated CD8+ cells detected by microarray. (P) expression 
level of BTN3A2 in CD8+ cells detected by qRT-PCR. (Q) expression level of 
VCAM1 in activated CD8+ cells detected by microarray. (R) expression level of 
VCAM1 in CD8+ cells detected by qRT-PCR. (S) expression level of ANXA2R in 
activated CD8+ cells detected by microarray. (T) expression level of ANXA2R in 
CD8+ cells detected by qRT-PCR. Lines indicate the geometric mean in 
expression level per each group. 
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